Spyre Therapeutics, Inc.

As of June 30, 2026, Spyre Therapeutics, Inc carries a market capitalization of 6.96B, placing it among publicly traded companies globally. Its enterprise value stands at 6.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Spyre Therapeutics, Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Spyre Therapeutics, Inc has 88.06M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Spyre Therapeutics, Inc maintains a current ratio of 18.53, meaning it holds 18.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Spyre Therapeutics, Inc posted a negative return on equity (ROE) of -28.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.90, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 92.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Spyre Therapeutics, Inc's stock has gained approximately 309.09% over the past 52 weeks. The 50-day moving average sits at 78.38, while the 200-day moving average is 61.72.

Over the twelve months ended June 30, 2026, Spyre Therapeutics, Inc generated - - in revenue and converted that into -156.61M in net income, yielding earnings per share of -2.09. EBITDA reached -176.23M, while operating income came in at -237.50M.

These figures are as of June 30, 2026. Total book value stands at 835.66M, with working capital of 971.32M providing operational flexibility.

Spyre Therapeutics, Inc produced -182.89M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.47, meaning Spyre Therapeutics, Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Spyre Therapeutics, Inc's most recent stock split took place on September 8, 2023 with a 25:1 split ratio.

As of June 30, 2026, Spyre Therapeutics, Inc has an Altman Z-Score of 65.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.